Cumulus Neuroscience published results from its CNS-101 study in Frontiers in Digital Health, reporting that its NeuLogiq platform was feasible, well tolerated, and usable for at-home cognitive and EEG assessment in people with mild Alzheimer's disease. The 52-week study, designed with ten pharmaceutical companies and run with the University of Cambridge, combines a wireless EEG headset with tablet-based cognitive tasks to capture frequent, longitudinal data outside the clinic.